[{"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-001", "question": "A 52-year-old woman with primary sclerosing cholangitis and ulcerative colitis presents with progressive fatigue and pruritus. Laboratory studies show alkaline phosphatase 892 U/L, total bilirubin 4.2 mg/dL, and CA 19-9 of 285 U/mL. MRCP reveals a dominant stricture at the hepatic duct bifurcation with upstream biliary dilation. Brush cytology obtained during ERCP shows atypical cells suspicious for malignancy. Fluorescence in situ hybridization (FISH) analysis demonstrates polysomy. Which additional finding on FISH would most strongly support a diagnosis of cholangiocarcinoma over reactive atypia in this clinical context?", "options": ["Homozygous deletion of 9p21 (CDKN2A/p16)", "Trisomy of chromosome 7", "Monosomy of chromosome 17", "Gain of chromosome 3", "Deletion of 1p36"], "answer": "A", "answer_index": 0, "explanation": "Homozygous deletion of 9p21 (CDKN2A/p16) detected by FISH has the highest specificity (approaching 100%) for cholangiocarcinoma in the setting of PSC with indeterminate biliary strictures. While polysomy alone increases suspicion for malignancy, it can occur in reactive conditions. Trisomy 7 and other chromosomal gains are less specific. The combination of polysomy plus 9p21 homozygous deletion essentially confirms malignancy in this high-risk population.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: patient with PSC, dominant stricture at hepatic duct bifurcation, atypical cells suspicious for malignancy, and FISH polysomy. The question asks which additional FISH finding most strongly supports cholangiocarcinoma over reactive atypia. The keyed answer (A) is correct: homozygous deletion of 9p21 (CDKN2A/p16) is the most specific cytogenetic marker for cholangiocarcinoma in PSC, as supported by guidelines and literature. Alternatives (B–E) are less specific chromosomal abnormalities commonly seen in reactive conditions or other cancers. No logical contradictions or underspecification exist. Medical accuracy is high, aligning with current diagnostic standards. Minimal fix: none required; item is clear and accurate.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: patient with PSC, dominant stricture at hepatic duct bifurcation, atypical cells suspicious for malignancy, and FISH polysomy. The question asks which additional FISH finding most strongly supports cholangiocarcinoma over reactive atypia. The keyed answer (A) is correct: homozygous deletion of 9p21 (CDKN2A/p16) is the most specific cytogenetic marker for cholangiocarcinoma in PSC, as supported by guidelines and literature. Alternatives (B–E) are less specific chromosomal abnormalities commonly seen in reactive conditions or other cancers. No logical contradictions or underspecification exist. Medical accuracy is high, aligning with current diagnostic standards. Minimal fix: none required; item is clear and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-002", "question": "A 38-year-old man undergoes evaluation for chronic diarrhea and weight loss. Small bowel biopsy reveals villous atrophy with increased intraepithelial lymphocytes. Despite strict gluten-free diet adherence confirmed by negative tissue transglutaminase antibodies for 18 months, symptoms persist. Repeat biopsy shows persistent villous atrophy with aberrant intraepithelial lymphocytes lacking surface CD3 but expressing cytoplasmic CD3, CD7, and CD103, with loss of CD8. T-cell receptor gene rearrangement studies show a monoclonal population. Which therapeutic approach offers the best chance of inducing remission before consideration of autologous stem cell transplantation?", "options": ["Budesonide 9 mg daily", "Cladribine-based chemotherapy", "Infliximab induction and maintenance", "Azathioprine 2.5 mg/kg daily", "Mesalamine 4.8 g daily"], "answer": "B", "answer_index": 1, "explanation": "This patient has Type II refractory celiac disease (RCD II), characterized by aberrant intraepithelial lymphocytes with the described immunophenotype (surface CD3-negative, cytoplasmic CD3-positive, CD8 loss) and monoclonal TCR rearrangement. RCD II has high risk of progression to enteropathy-associated T-cell lymphoma. Cladribine (2-CdA), a purine analog, has shown the best response rates (approximately 40-50%) in inducing histologic and clinical remission in RCD II and serves as a bridge to autologous stem cell transplantation. Steroids, immunomodulators, and biologics used in RCD I are ineffective in RCD II.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: chronic diarrhea with persistent villous atrophy despite confirmed gluten-free diet and negative tTG antibodies; aberrant IEL immunophenotype (surface CD3-, cytoplasmic CD3+, CD8 loss, CD103+); monoclonal TCR rearrangement. These findings definitively diagnose type II refractory celiac disease (RCD II), a clonal pre-lymphomatous disorder. Main logical issue: None; the stem provides a classic, specific presentation for RCD II. Main medical accuracy issue: None; the keyed answer (cladribine-based chemotherapy) aligns with current guidelines as the best initial therapy to induce remission before stem cell transplant for RCD II. Minimal fix: None required; the item is already unambiguous and accurate. Alternatives are correctly inferior: steroids (A) and immunomodulators (D) are for RCD I; anti-TNF (C) and mesalamine (E) are not indicated.\",\n  \"medical_accuracy_score\":  \"5\",\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: chronic diarrhea with persistent villous atrophy despite confirmed gluten-free diet and negative tTG antibodies; aberrant IEL immunophenotype (surface CD3-, cytoplasmic CD3+, CD8 loss, CD103+); monoclonal TCR rearrangement. These findings definitively diagnose type II refractory celiac disease (RCD II), a clonal pre-lymphomatous disorder. Main logical issue: None; the stem provides a classic, specific presentation for RCD II. Main medical accuracy issue: None; the keyed answer (cladribine-based chemotherapy) aligns with current guidelines as the best initial therapy to induce remission before stem cell transplant for RCD II. Minimal fix: None required; the item is already unambiguous and accurate. Alternatives are correctly inferior: steroids (A) and immunomodulators (D) are for RCD I; anti-TNF (C) and mesalamine (E) are not indicated.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-003", "question": "A 45-year-old woman with lupus nephritis class IV on mycophenolate mofetil and prednisone develops acute kidney injury with serum creatinine rising from 1.2 to 3.8 mg/dL over 2 weeks. Urinalysis shows 3+ protein, numerous dysmorphic RBCs, and RBC casts. Complement levels are normal and anti-dsDNA titers are stable. Kidney biopsy reveals crescentic glomerulonephritis with linear IgG staining along the glomerular basement membrane, with concurrent immune complex deposits in the mesangium. Anti-GBM antibodies are positive at 85 EU (normal <20). Which statement best characterizes this clinical entity?", "options": ["This represents lupus flare requiring intensification of immunosuppression alone", "The linear IgG staining is an artifact from prior immune complex deposition", "This is anti-GBM disease superimposed on lupus nephritis requiring plasmapheresis", "Concurrent ANCA-associated vasculitis is the most likely explanation", "The anti-GBM antibodies are false-positive due to cross-reactivity with dsDNA"], "answer": "C", "answer_index": 2, "explanation": "This patient has developed anti-GBM disease superimposed on pre-existing lupus nephritis, a rare but well-documented phenomenon. The linear IgG staining pattern is pathognomonic for anti-GBM disease and distinct from the granular pattern of lupus nephritis. The presence of positive anti-GBM antibodies confirms the diagnosis. Treatment requires plasmapheresis to remove circulating anti-GBM antibodies in addition to immunosuppression. Normal complements and stable anti-dsDNA argue against lupus flare as the sole explanation. Anti-GBM antibodies target the NC1 domain of type IV collagen and do not cross-react with dsDNA.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: acute kidney injury with crescents, linear IgG staining on biopsy, positive anti-GBM antibodies, and pre-existing lupus nephritis with stable serology (normal complement, stable anti-dsDNA). These findings are pathognomonic for superimposed anti-GBM disease, not a lupus flare. The item is logically valid: the unique best answer (C) is clearly supported by the combination of linear staining and positive anti-GBM serology in this clinical context. Medical accuracy is high, reflecting a rare but documented entity. The rationale correctly notes the need for plasmapheresis. A minimal fix is not required, but specifying the absence of ANCA serology could preempt option D, though the linear staining pattern already strongly favors anti-GBM disease.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: acute kidney injury with crescents, linear IgG staining on biopsy, positive anti-GBM antibodies, and pre-existing lupus nephritis with stable serology (normal complement, stable anti-dsDNA). These findings are pathognomonic for superimposed anti-GBM disease, not a lupus flare. The item is logically valid: the unique best answer (C) is clearly supported by the combination of linear staining and positive anti-GBM serology in this clinical context. Medical accuracy is high, reflecting a rare but documented entity. The rationale correctly notes the need for plasmapheresis. A minimal fix is not required, but specifying the absence of ANCA serology could preempt option D, though the linear staining pattern already strongly favors anti-GBM disease.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-004", "question": "A 62-year-old man with myelodysplastic syndrome with excess blasts-2 (MDS-EB2) undergoes allogeneic hematopoietic stem cell transplantation from a matched unrelated donor. On day +45, he develops progressive pancytopenia with WBC 0.8 × 10⁹/L, hemoglobin 7.2 g/dL, and platelets 12 × 10⁹/L. Bone marrow biopsy shows hypocellularity (10%) with no evidence of relapsed MDS. Chimerism analysis reveals 100% donor cells. Cytomegalovirus and HHV-6 PCR are negative. Which mechanism most likely explains this patient's graft failure?", "options": ["Donor-derived clonal hematopoiesis with DDX41 germline mutation", "Secondary hemophagocytic lymphohistiocytosis", "Graft-versus-host disease affecting the bone marrow stroma", "Residual host T-cell mediated rejection despite full donor chimerism", "Drug-induced marrow suppression from valganciclovir prophylaxis"], "answer": "A", "answer_index": 0, "explanation": "Donor-derived clonal hematopoiesis from germline mutations (particularly DDX41) in the donor can cause graft failure or donor-derived MDS/AML post-transplant. DDX41 mutations are increasingly recognized as a cause of familial MDS/AML and can be present in phenotypically normal donors. The 100% donor chimerism excludes host-mediated rejection. The absence of CMV/HHV-6 and the clinical context make drug toxicity less likely. HLH would typically show additional features (ferritin elevation, hepatosplenomegaly). Marrow stromal GVHD is rare and would not explain isolated hematopoietic failure with full donor chimerism.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. The keyed answer (A) is not the most defensible best answer. The stem describes late graft failure (day +45) with pancytopenia, hypocellular marrow, 100% donor chimerism, and no infection. The most likely mechanism in this classic presentation is drug-induced marrow suppression from valganciclovir (E), a well-known cause of late cytopenias post-transplant, especially with the given cell counts. Option A (donor-derived clonal hematopoiesis) is a rare, speculative cause not supported by the stem's lack of dysplastic or clonal findings. The rationale incorrectly dismisses drug toxicity. Main logical issue: The key does not match the single best answer supported by standard transplant knowledge. Minimal fix: Change the key to E (Drug-induced marrow suppression from valganciclovir prophylaxis) and adjust the rationale accordingly.\",\n  \"logical_false_reason\": \"K\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \"2\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. The keyed answer (A) is not the most defensible best answer. The stem describes late graft failure (day +45) with pancytopenia, hypocellular marrow, 100% donor chimerism, and no infection. The most likely mechanism in this classic presentation is drug-induced marrow suppression from valganciclovir (E), a well-known cause of late cytopenias post-transplant, especially with the given cell counts. Option A (donor-derived clonal hematopoiesis) is a rare, speculative cause not supported by the stem's lack of dysplastic or clonal findings. The rationale incorrectly dismisses drug toxicity. Main logical issue: The key does not match the single best answer supported by standard transplant knowledge. Minimal fix: Change the key to E (Drug-induced marrow suppression from valganciclovir prophylaxis) and adjust the rationale accordingly.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-005", "question": "A 28-year-old woman presents with recurrent sinopulmonary infections since childhood, chronic diarrhea, and splenomegaly. Laboratory evaluation reveals IgG 180 mg/dL (normal 700-1600), IgA <7 mg/dL, IgM 320 mg/dL (normal 40-230), and absent isohemagglutinins. Flow cytometry shows normal B-cell numbers but absent CD27+ memory B cells. Genetic testing reveals a hemizygous mutation in CD40LG. Her brother has similar symptoms. Which finding would be most unexpected in this patient?", "options": ["Cryptosporidium parvum cholangiopathy", "Pneumocystis jirovecii pneumonia", "Germinal center formation on lymph node biopsy", "Neutropenia", "Elevated liver enzymes"], "answer": "C", "answer_index": 2, "explanation": "This patient has X-linked hyper-IgM syndrome (HIGM1) due to CD40LG mutation, which can occur in females due to skewed X-inactivation or homozygosity. CD40L-CD40 interaction is essential for germinal center formation, class-switch recombination, and somatic hypermutation. Therefore, germinal center formation would be absent on lymph node biopsy. Cryptosporidium cholangiopathy, PCP, neutropenia (due to impaired granulopoiesis), and elevated liver enzymes (from sclerosing cholangitis or hepatitis) are all well-documented complications of HIGM1.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: recurrent sinopulmonary infections, chronic diarrhea, splenomegaly, low IgG, low IgA, elevated IgM, absent isohemagglutinins, normal B-cell numbers but absent CD27+ memory B cells, hemizygous CD40LG mutation, X-linked inheritance pattern. These findings definitively diagnose X-linked hyper-IgM syndrome type 1 (HIGM1). The question asks for the 'most unexpected' finding. In HIGM1, defective CD40L-CD40 interaction prevents germinal center formation, making option C (Germinal center formation) the expected finding to be absent, not unexpected. The keyed answer (C) is therefore the opposite of correct. Options A, B, D, and E are all well-documented complications and would be expected. The unique best answer is not C. Main logical issue: The key does not match the single best answer defensible from the vignette. Main medical accuracy: The pathophysiological association is accurate, but the key is inverted. Minimal fix: Change the key to any option other than C (e.g., a finding not associated with HIGM1) or rephrase the stem to ask for the 'most expected' finding.\",\n  \"medical_accuracy_score\":  \"4\",\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: recurrent sinopulmonary infections, chronic diarrhea, splenomegaly, low IgG, low IgA, elevated IgM, absent isohemagglutinins, normal B-cell numbers but absent CD27+ memory B cells, hemizygous CD40LG mutation, X-linked inheritance pattern. These findings definitively diagnose X-linked hyper-IgM syndrome type 1 (HIGM1). The question asks for the 'most unexpected' finding. In HIGM1, defective CD40L-CD40 interaction prevents germinal center formation, making option C (Germinal center formation) the expected finding to be absent, not unexpected. The keyed answer (C) is therefore the opposite of correct. Options A, B, D, and E are all well-documented complications and would be expected. The unique best answer is not C. Main logical issue: The key does not match the single best answer defensible from the vignette. Main medical accuracy: The pathophysiological association is accurate, but the key is inverted. Minimal fix: Change the key to any option other than C (e.g., a finding not associated with HIGM1) or rephrase the stem to ask for the 'most expected' finding.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-006", "question": "A 34-year-old man from the Ohio River Valley presents with 3 weeks of fever, night sweats, and 15-pound weight loss. He has a history of HIV infection with CD4 count of 45 cells/μL and is not on antiretroviral therapy. Physical examination reveals hepatosplenomegaly and diffuse lymphadenopathy. Laboratory studies show pancytopenia and LDH 1,850 U/L. Bone marrow biopsy reveals small intracellular yeast forms within macrophages. Urine Histoplasma antigen is strongly positive. He is started on liposomal amphotericin B. On day 3 of treatment, he develops high fever, hypotension, and worsening respiratory status despite negative blood cultures and improving fungal markers. Which intervention is most appropriate?", "options": ["Add voriconazole for possible amphotericin-resistant Histoplasma", "Initiate corticosteroids for immune reconstitution inflammatory syndrome", "Switch to itraconazole due to amphotericin B toxicity", "Add broad-spectrum antibiotics for bacterial superinfection", "Delay antiretroviral therapy initiation for at least 4 weeks"], "answer": "B", "answer_index": 1, "explanation": "This patient is experiencing paradoxical worsening consistent with immune reconstitution inflammatory syndrome (IRIS), which can occur in severely immunocompromised HIV patients even before ART initiation (unmasking IRIS) or represent early inflammatory response to effective antifungal therapy. The improving fungal markers argue against treatment failure or resistance. Corticosteroids (prednisone 0.5-1 mg/kg) are the treatment of choice for moderate-to-severe IRIS. While ART timing is important, the immediate management of IRIS takes precedence. Amphotericin B resistance in Histoplasma is exceedingly rare.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: HIV with CD4 45, disseminated histoplasmosis on liposomal amphotericin B, day 3 of treatment, high fever/hypotension/worsening respiratory status, negative blood cultures, improving fungal markers. This temporal pattern of clinical deterioration despite microbiologic improvement is classic for unmasking IRIS. Main logical issue: None; the vignette provides sufficient detail to uniquely identify IRIS as the cause and corticosteroid initiation as the most appropriate intervention. Main medical accuracy issue: None; the diagnosis and management align with IDSA guidelines. Minimal fix: None required; the item is well-constructed. Alternative rationales are weaker: A (resistance is rare and markers are improving), C (toxicity typically presents differently and markers are improving), D (cultures are negative), E (ART timing is a secondary concern after managing acute IRIS).\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: HIV with CD4 45, disseminated histoplasmosis on liposomal amphotericin B, day 3 of treatment, high fever/hypotension/worsening respiratory status, negative blood cultures, improving fungal markers. This temporal pattern of clinical deterioration despite microbiologic improvement is classic for unmasking IRIS. Main logical issue: None; the vignette provides sufficient detail to uniquely identify IRIS as the cause and corticosteroid initiation as the most appropriate intervention. Main medical accuracy issue: None; the diagnosis and management align with IDSA guidelines. Minimal fix: None required; the item is well-constructed. Alternative rationales are weaker: A (resistance is rare and markers are improving), C (toxicity typically presents differently and markers are improving), D (cultures are negative), E (ART timing is a secondary concern after managing acute IRIS).", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-007", "question": "A 58-year-old woman with metastatic HER2-positive breast cancer on trastuzumab deruxtecan develops progressive dyspnea over 4 weeks. CT chest reveals bilateral ground-glass opacities with a peripheral and lower lobe predominant distribution. Bronchoalveolar lavage shows lymphocytic predominance with CD4/CD8 ratio of 0.5. Infectious workup is negative. She is diagnosed with drug-induced interstitial lung disease. After drug discontinuation and corticosteroid initiation, her symptoms improve. Three months later, restaging shows disease progression. Which factor most strongly supports rechallenge with trastuzumab deruxtecan?", "options": ["Initial ILD grade was 1 with complete radiographic resolution", "Absence of anti-drug antibodies on serologic testing", "HER2 amplification ratio >6 on repeat biopsy", "Negative rechallenge skin testing to the drug", "Normal pulmonary function tests at baseline before rechallenge"], "answer": "A", "answer_index": 0, "explanation": "Rechallenge with trastuzumab deruxtecan after ILD is a complex decision. Per consensus guidelines, rechallenge may be considered only in patients who experienced Grade 1 ILD that completely resolved both clinically and radiographically. Higher grade ILD (Grade 2-4) is generally considered a contraindication to rechallenge. Anti-drug antibodies, HER2 status, skin testing, and baseline PFTs do not reliably predict ILD recurrence risk. The mechanism of T-DXd-associated ILD is not fully understood but appears related to the topoisomerase I inhibitor payload rather than immune-mediated hypersensitivity.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict: Correct best. Key stem clues: patient had drug-induced ILD, improved after discontinuation/steroids, now has progression. The question asks which factor most strongly supports rechallenge. Guidelines indicate rechallenge may be considered only for Grade 1 ILD with complete resolution, making A the unique best answer. Options B, C, D, and E are not established predictors of safe rechallenge. The item is logically valid and medically accurate, aligning with consensus management. No contradictions or underspecification. Minimal fix: none required; item is clear and defensible.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. Key stem clues: patient had drug-induced ILD, improved after discontinuation/steroids, now has progression. The question asks which factor most strongly supports rechallenge. Guidelines indicate rechallenge may be considered only for Grade 1 ILD with complete resolution, making A the unique best answer. Options B, C, D, and E are not established predictors of safe rechallenge. The item is logically valid and medically accurate, aligning with consensus management. No contradictions or underspecification. Minimal fix: none required; item is clear and defensible.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-008", "question": "A 42-year-old woman with a history of chronic rhinosinusitis and nasal polyps presents with new-onset asthma requiring systemic corticosteroids. She reports severe reactions to aspirin and ibuprofen characterized by bronchospasm and nasal congestion. She requires hip replacement surgery and the orthopedic surgeon requests clearance for perioperative ketorolac use. After shared decision-making, aspirin desensitization is planned. During the desensitization protocol, she develops bronchospasm at the 60 mg aspirin dose. Which mediator's urinary metabolite would be most elevated during this reaction?", "options": ["Leukotriene E4", "Prostaglandin D2 (as 11β-prostaglandin F2α)", "Histamine (as N-methylhistamine)", "Tryptase", "Platelet-activating factor"], "answer": "A", "answer_index": 0, "explanation": "Aspirin-exacerbated respiratory disease (AERD) is characterized by overproduction of cysteinyl leukotrienes (CysLTs) due to dysregulated arachidonic acid metabolism. During aspirin-induced reactions in AERD, urinary leukotriene E4 (LTE4), the stable end-metabolite of CysLTs, increases dramatically (often 3-10 fold). This distinguishes AERD from IgE-mediated reactions where prostaglandin D2 metabolites and histamine metabolites predominate. Tryptase elevation suggests mast cell degranulation in anaphylaxis but is not characteristic of AERD reactions. The CysLT pathway is the primary driver of bronchoconstriction in AERD.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: history of chronic rhinosinusitis, nasal polyps, asthma, and severe respiratory reactions to NSAIDs (aspirin/ibuprofen) defines aspirin-exacerbated respiratory disease (AERD). During an aspirin desensitization reaction, the pathophysiologic hallmark is overproduction of cysteinyl leukotrienes. Main logical issue: None; the vignette is specific and consistent. Main medical accuracy issue: None; the association of urinary LTE4 elevation with AERD reactions is well-established. Minimal fix: No fix needed; the item is clear, accurate, and supports a single best answer.\",\n  \"medical_accuracy_score\":  \"5\",\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: history of chronic rhinosinusitis, nasal polyps, asthma, and severe respiratory reactions to NSAIDs (aspirin/ibuprofen) defines aspirin-exacerbated respiratory disease (AERD). During an aspirin desensitization reaction, the pathophysiologic hallmark is overproduction of cysteinyl leukotrienes. Main logical issue: None; the vignette is specific and consistent. Main medical accuracy issue: None; the association of urinary LTE4 elevation with AERD reactions is well-established. Minimal fix: No fix needed; the item is clear, accurate, and supports a single best answer.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-009", "question": "An 82-year-old woman with moderate Alzheimer's dementia (MMSE 18) living in assisted living is hospitalized for community-acquired pneumonia. On hospital day 2, she becomes acutely agitated with visual hallucinations. Her medications include donepezil, memantine, and lisinopril. She is started on haloperidol 0.5 mg for agitation. On day 3, she develops temperature 39.2°C, severe muscle rigidity, diaphoresis, and altered consciousness. Laboratory studies show CK 8,500 U/L and WBC 14,000/μL. Which mechanism best explains this presentation?", "options": ["Anticholinergic toxicity from haloperidol-donepezil interaction", "Dopamine receptor blockade causing neuroleptic malignant syndrome", "Serotonin syndrome from memantine-haloperidol interaction", "Malignant hyperthermia triggered by infection", "Central fever from hypothalamic involvement by infection"], "answer": "B", "answer_index": 1, "explanation": "This patient has developed neuroleptic malignant syndrome (NMS) following haloperidol administration, characterized by the classic tetrad of hyperthermia, severe rigidity, altered mental status, and autonomic instability with elevated CK. Elderly patients with dementia are at increased risk for NMS. The mechanism is dopamine D2 receptor blockade in the hypothalamus and nigrostriatal pathways. While donepezil increases acetylcholine (potentially worsening extrapyramidal symptoms), the presentation is classic for NMS rather than anticholinergic toxicity. Memantine is an NMDA antagonist with minimal serotonergic activity, making serotonin syndrome unlikely.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: acute agitation in elderly dementia patient, recent low-dose haloperidol initiation, followed by classic NMS tetrad (fever, severe rigidity, autonomic instability, altered consciousness) with marked CK elevation. The presentation is textbook for neuroleptic malignant syndrome (NMS) from dopamine D2 blockade. Main logical issue: None; the vignette uniquely supports NMS. Main medical accuracy issue: Minor—while NMS risk is elevated in dementia, the provided explanation overstates the specific risk from donepezil interaction. Minimal fix: Clarify that haloperidol is the sole proximate cause; remove speculative interaction language from rationale to avoid overcomplication.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\": \n  \"4\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: acute agitation in elderly dementia patient, recent low-dose haloperidol initiation, followed by classic NMS tetrad (fever, severe rigidity, autonomic instability, altered consciousness) with marked CK elevation. The presentation is textbook for neuroleptic malignant syndrome (NMS) from dopamine D2 blockade. Main logical issue: None; the vignette uniquely supports NMS. Main medical accuracy issue: Minor—while NMS risk is elevated in dementia, the provided explanation overstates the specific risk from donepezil interaction. Minimal fix: Clarify that haloperidol is the sole proximate cause; remove speculative interaction language from rationale to avoid overcomplication.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-010", "question": "A 55-year-old man with cirrhosis secondary to alcohol use disorder and hepatocellular carcinoma (single 3.5 cm lesion, no vascular invasion, AFP 450 ng/mL) undergoes liver transplantation. Explant pathology confirms a single 3.8 cm moderately differentiated HCC without microvascular invasion. Eighteen months post-transplant, surveillance imaging reveals a 2.2 cm lung nodule. Biopsy confirms metastatic HCC. His current immunosuppression includes tacrolimus and mycophenolate mofetil. Which modification to his immunosuppressive regimen is most strongly supported by evidence for managing this recurrence?", "options": ["Conversion from tacrolimus to cyclosporine", "Addition of belatacept to current regimen", "Conversion from tacrolimus to sirolimus", "Discontinuation of all immunosuppression", "Addition of azathioprine to current regimen"], "answer": "C", "answer_index": 2, "explanation": "Conversion from calcineurin inhibitors (tacrolimus) to mTOR inhibitors (sirolimus/everolimus) is recommended in post-transplant HCC recurrence. mTOR inhibitors have direct antitumor effects through inhibition of the PI3K/AKT/mTOR pathway, which is frequently dysregulated in HCC. Multiple studies have shown improved outcomes with mTOR inhibitor-based immunosuppression in HCC recurrence. Complete immunosuppression withdrawal risks allograft rejection without proven oncologic benefit. Cyclosporine, belatacept, and azathioprine lack the antitumor properties of mTOR inhibitors.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: post-liver transplant HCC recurrence, currently on tacrolimus + mycophenolate, question asks for evidence-supported immunosuppression modification for managing recurrence. The stem clearly establishes a scenario of HCC recurrence after transplant, directing focus to immunosuppression strategies with antitumor effects. Sirolimus (mTOR inhibitor) is uniquely supported by evidence for this specific context due to its antiproliferative properties. Alternatives lack comparable evidence: cyclosporine is another calcineurin inhibitor without proven benefit; belatacept/azathioprine lack specific antitumor data; discontinuation risks rejection. No internal contradictions or missing critical details. Medical accuracy is sound, aligning with transplant oncology guidelines. Minimal fix: none required; item is logically valid and medically accurate.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: post-liver transplant HCC recurrence, currently on tacrolimus + mycophenolate, question asks for evidence-supported immunosuppression modification for managing recurrence. The stem clearly establishes a scenario of HCC recurrence after transplant, directing focus to immunosuppression strategies with antitumor effects. Sirolimus (mTOR inhibitor) is uniquely supported by evidence for this specific context due to its antiproliferative properties. Alternatives lack comparable evidence: cyclosporine is another calcineurin inhibitor without proven benefit; belatacept/azathioprine lack specific antitumor data; discontinuation risks rejection. No internal contradictions or missing critical details. Medical accuracy is sound, aligning with transplant oncology guidelines. Minimal fix: none required; item is logically valid and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-011", "question": "A 48-year-old woman with Crohn's disease on vedolizumab presents with 6 months of progressive fatigue, exertional dyspnea, and paresthesias in her feet. Laboratory studies reveal hemoglobin 8.2 g/dL, MCV 118 fL, reticulocyte count 1.2%, LDH 890 U/L, and indirect bilirubin 2.1 mg/dL. Peripheral smear shows macro-ovalocytes and hypersegmented neutrophils. Vitamin B12 level is 85 pg/mL (normal >200). Anti-intrinsic factor antibodies are negative. She has no history of gastric surgery. Upper endoscopy with gastric biopsy shows chronic atrophic gastritis with intestinal metaplasia but no Helicobacter pylori. Which additional finding would most strongly suggest an autoimmune etiology despite negative anti-IF antibodies?", "options": ["Elevated serum gastrin level >1000 pg/mL", "Presence of anti-parietal cell antibodies", "Low serum pepsinogen I with normal pepsinogen II", "Enterochromaffin-like cell hyperplasia on biopsy", "Positive anti-Saccharomyces cerevisiae antibodies"], "answer": "C", "answer_index": 2, "explanation": "Low serum pepsinogen I (PGI) with normal pepsinogen II (PGII), resulting in a low PGI/PGII ratio, is highly specific for corpus-predominant atrophic gastritis characteristic of autoimmune gastritis. PGI is produced exclusively by chief cells in the corpus, which are destroyed in autoimmune gastritis. Anti-IF antibodies have only 50-70% sensitivity for pernicious anemia. Anti-parietal cell antibodies are more sensitive but less specific. Elevated gastrin and ECL hyperplasia occur in autoimmune gastritis but are consequences rather than diagnostic markers. ASCA is associated with Crohn's disease, not autoimmune gastritis.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: chronic atrophic gastritis with intestinal metaplasia on biopsy, negative anti-intrinsic factor antibodies, no H. pylori, no gastric surgery, and low B12 with macrocytic anemia. The question asks for the finding most strongly suggesting autoimmune etiology despite negative anti-IF antibodies. Low pepsinogen I with normal pepsinogen II is a specific marker for corpus-predominant atrophic gastritis, aligning with autoimmune gastritis. Other options are less specific (anti-parietal cell antibodies), consequences rather than diagnostic (elevated gastrin, ECL hyperplasia), or irrelevant (ASCA). No logical contradictions or missing critical details; the key is uniquely defensible. Medical accuracy is sound. Minimal fix: none required.\",\n  \"medical_accuracy_score\":  \"5\",\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: chronic atrophic gastritis with intestinal metaplasia on biopsy, negative anti-intrinsic factor antibodies, no H. pylori, no gastric surgery, and low B12 with macrocytic anemia. The question asks for the finding most strongly suggesting autoimmune etiology despite negative anti-IF antibodies. Low pepsinogen I with normal pepsinogen II is a specific marker for corpus-predominant atrophic gastritis, aligning with autoimmune gastritis. Other options are less specific (anti-parietal cell antibodies), consequences rather than diagnostic (elevated gastrin, ECL hyperplasia), or irrelevant (ASCA). No logical contradictions or missing critical details; the key is uniquely defensible. Medical accuracy is sound. Minimal fix: none required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-012", "question": "A 52-year-old man with IgA nephropathy and eGFR 35 mL/min/1.73m² is enrolled in a clinical trial evaluating a novel targeted-release formulation of budesonide (NEFECON). After 9 months of treatment, his 24-hour urine protein decreases from 2.8 g to 0.9 g, and eGFR stabilizes. Repeat kidney biopsy shows reduced mesangial IgA deposits and decreased mesangial hypercellularity. Which mechanism best explains the therapeutic effect of this formulation in IgA nephropathy?", "options": ["Systemic immunosuppression reducing circulating galactose-deficient IgA1", "Direct podocyte stabilization through glucocorticoid receptor activation", "Targeted delivery to Peyer's patches reducing mucosal IgA production", "Inhibition of complement activation at the glomerular level", "Suppression of bone marrow plasma cells producing pathogenic IgA1"], "answer": "C", "answer_index": 2, "explanation": "NEFECON (targeted-release budesonide) is formulated to release budesonide in the distal ileum where Peyer's patches are concentrated. The pathogenesis of IgA nephropathy involves mucosal immune dysregulation with production of galactose-deficient IgA1 (Gd-IgA1) primarily in gut-associated lymphoid tissue (GALT). By targeting Peyer's patches, NEFECON reduces the source of pathogenic Gd-IgA1 production while minimizing systemic corticosteroid exposure due to high first-pass hepatic metabolism. This mucosal-targeted approach distinguishes it from systemic immunosuppression strategies.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed. The keyed answer (C) is plausible but not uniquely best. The stem describes a patient with IgA nephropathy treated with NEFECON, showing reduced proteinuria, stabilized eGFR, and decreased mesangial IgA deposits and hypercellularity on biopsy. The question asks for the mechanism best explaining the therapeutic effect. While C (targeted delivery to Peyer's patches reducing mucosal IgA production) is a known proposed mechanism for NEFECON, option A (systemic immunosuppression reducing circulating galactose-deficient IgA1) is also strongly defensible. Budesonide, even with targeted release and high first-pass metabolism, has some systemic bioavailability and glucocorticoid effects that could reduce pathogenic IgA1. The biopsy findings of reduced deposits and hypercellularity are consistent with both reduced IgA production (C) and systemic immunosuppressive effects (A). The item is underspecified (U) in not providing data to distinguish between local mucosal vs. systemic mechanisms, leading to multiple defensible answers (M). Minimal fix: Revise the stem to include a specific finding that rules out systemic effects, e.g., 'Serum cortisol and lymphocyte counts remain normal, and plasma Gd-IgA1 levels are unchanged.'\",\n  \"logical_false_reason\": \"K\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \"4\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed. The keyed answer (C) is plausible but not uniquely best. The stem describes a patient with IgA nephropathy treated with NEFECON, showing reduced proteinuria, stabilized eGFR, and decreased mesangial IgA deposits and hypercellularity on biopsy. The question asks for the mechanism best explaining the therapeutic effect. While C (targeted delivery to Peyer's patches reducing mucosal IgA production) is a known proposed mechanism for NEFECON, option A (systemic immunosuppression reducing circulating galactose-deficient IgA1) is also strongly defensible. Budesonide, even with targeted release and high first-pass metabolism, has some systemic bioavailability and glucocorticoid effects that could reduce pathogenic IgA1. The biopsy findings of reduced deposits and hypercellularity are consistent with both reduced IgA production (C) and systemic immunosuppressive effects (A). The item is underspecified (U) in not providing data to distinguish between local mucosal vs. systemic mechanisms, leading to multiple defensible answers (M). Minimal fix: Revise the stem to include a specific finding that rules out systemic effects, e.g., 'Serum cortisol and lymphocyte counts remain normal, and plasma Gd-IgA1 levels are unchanged.'", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-013", "question": "A 67-year-old man with JAK2 V617F-positive polycythemia vera on hydroxyurea for 8 years presents with progressive splenomegaly, worsening anemia (hemoglobin 8.5 g/dL), and new circulating blasts (6%). Bone marrow biopsy shows 30% cellularity with grade 3 reticulin fibrosis, 8% blasts, and megakaryocyte clustering with atypia. Cytogenetics reveal del(5q), +8, and a new TP53 mutation is detected. Which statement most accurately characterizes his prognosis and optimal management?", "options": ["This represents post-PV myelofibrosis; ruxolitinib will improve survival", "This is post-PV acute myeloid leukemia; intensive chemotherapy is indicated", "This is accelerated phase disease; allogeneic transplant offers best survival", "The TP53 mutation predicts excellent response to hypomethylating agents", "Luspatercept should be initiated for the anemia before other interventions"], "answer": "C", "answer_index": 2, "explanation": "This patient has post-PV myelofibrosis in accelerated phase (10-19% blasts defines accelerated phase; ≥20% defines blast phase/AML). The presence of TP53 mutation, complex cytogenetics including del(5q), and high-risk features confer extremely poor prognosis. Allogeneic stem cell transplantation is the only potentially curative option, though outcomes remain poor with TP53 mutations. Ruxolitinib provides symptomatic benefit but does not improve survival in accelerated/blast phase. TP53 mutations predict poor response to hypomethylating agents and chemotherapy. Luspatercept addresses anemia but not the underlying disease progression.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: JAK2+ PV, hydroxyurea history, progressive splenomegaly, worsening anemia, 8% blasts in marrow, grade 3 fibrosis, high-risk cytogenetics (del5q, +8), and new TP53 mutation. The stem describes post-PV myelofibrosis with 8% blasts, which is <10% and thus chronic phase, not accelerated phase (10-19% blasts). The keyed answer (C) incorrectly labels this as accelerated phase. A unique best answer exists: the scenario best fits high-risk myelofibrosis (not AML, not accelerated phase), making ruxolitinib (option A) the standard initial management for symptomatic myelofibrosis, though it does not improve survival in blast phase. The item's logic fails because it misclassifies the disease phase. Main medical issue: misapplication of blast percentage thresholds. Minimal fix: Change the marrow blast percentage in the stem to ≥10% to correctly define accelerated phase, making option C defensible.\",\n  \"logical_false_reason\": \"K\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \"3\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: JAK2+ PV, hydroxyurea history, progressive splenomegaly, worsening anemia, 8% blasts in marrow, grade 3 fibrosis, high-risk cytogenetics (del5q, +8), and new TP53 mutation. The stem describes post-PV myelofibrosis with 8% blasts, which is <10% and thus chronic phase, not accelerated phase (10-19% blasts). The keyed answer (C) incorrectly labels this as accelerated phase. A unique best answer exists: the scenario best fits high-risk myelofibrosis (not AML, not accelerated phase), making ruxolitinib (option A) the standard initial management for symptomatic myelofibrosis, though it does not improve survival in blast phase. The item's logic fails because it misclassifies the disease phase. Main medical issue: misapplication of blast percentage thresholds. Minimal fix: Change the marrow blast percentage in the stem to ≥10% to correctly define accelerated phase, making option C defensible.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-014", "question": "A 35-year-old man presents with recurrent bacterial sinopulmonary infections and chronic norovirus gastroenteritis. Laboratory evaluation reveals IgG 320 mg/dL, IgA 45 mg/dL, IgM 25 mg/dL, and absent specific antibody responses to pneumococcal polysaccharide and protein antigens despite vaccination. B-cell numbers are normal. Genetic testing reveals a heterozygous mutation in NFKB1. His 8-year-old daughter has similar symptoms. Which additional clinical manifestation is most characteristically associated with this genetic defect?", "options": ["Severe combined immunodeficiency in infancy", "Autoimmune cytopenias and lymphoproliferation", "Hyper-IgE syndrome with eczema and bone abnormalities", "Complement deficiency with recurrent Neisseria infections", "Chronic granulomatous disease with catalase-positive organisms"], "answer": "B", "answer_index": 1, "explanation": "NFKB1 haploinsufficiency is an autosomal dominant cause of common variable immunodeficiency (CVID). Beyond hypogammaglobulinemia and recurrent infections, NFKB1 deficiency is strongly associated with autoimmune manifestations, particularly autoimmune cytopenias (autoimmune hemolytic anemia, ITP) and lymphoproliferation including splenomegaly and lymphadenopathy. NF-κB signaling is critical for B-cell survival, class-switch recombination, and immune tolerance. The autosomal dominant inheritance pattern explains the affected daughter. SCID, hyper-IgE, complement deficiency, and CGD have distinct genetic etiologies and clinical presentations.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: autosomal dominant inheritance (affected daughter), hypogammaglobulinemia with poor vaccine response, normal B-cell numbers, and NFKB1 mutation—all classic for CVID due to NFKB1 haploinsufficiency. The question asks for the most characteristic additional manifestation, which is autoimmune cytopenias/lymphoproliferation (B), well-established in this genetic defect. No logical issues: the vignette is specific, options are distinct disorders. Medical accuracy is high, aligning with current literature. Minimal fix: none needed; item is clear and accurate.\",\n  \"medical_accuracy_score\":  \"5\",\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: autosomal dominant inheritance (affected daughter), hypogammaglobulinemia with poor vaccine response, normal B-cell numbers, and NFKB1 mutation—all classic for CVID due to NFKB1 haploinsufficiency. The question asks for the most characteristic additional manifestation, which is autoimmune cytopenias/lymphoproliferation (B), well-established in this genetic defect. No logical issues: the vignette is specific, options are distinct disorders. Medical accuracy is high, aligning with current literature. Minimal fix: none needed; item is clear and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-015", "question": "A 45-year-old woman from rural Peru presents with a 3-month history of progressive dysphagia, regurgitation, and 20-pound weight loss. Barium swallow shows a dilated esophagus with smooth tapering at the gastroesophageal junction (\"bird's beak\" appearance). Esophageal manometry reveals absent peristalsis and incomplete lower esophageal sphincter relaxation. Serologic testing for Trypanosoma cruzi is positive. Cardiac evaluation shows a dilated left ventricle with apical aneurysm and EF 35%. Which statement best characterizes the pathophysiology linking her esophageal and cardiac findings?", "options": ["Direct parasitic invasion of smooth muscle cells in both organs", "Autoimmune destruction of intramural neurons and cardiac myocytes", "Eosinophilic infiltration causing tissue fibrosis", "Vasculitis affecting the vasa nervorum and coronary arteries", "Toxin-mediated damage similar to diphtheria"], "answer": "B", "answer_index": 1, "explanation": "Chronic Chagas disease (American trypanosomiasis) causes megaesophagus and cardiomyopathy through autoimmune mechanisms. Molecular mimicry between T. cruzi antigens and host cardiac myosin, neuronal proteins, and other self-antigens triggers autoimmune destruction of intramural ganglion cells (Auerbach's plexus) in the esophagus and cardiac myocytes/conduction tissue. The apical aneurysm is pathognomonic for Chagas cardiomyopathy. Direct parasitic invasion occurs in acute phase but parasites are rarely found in chronic lesions. The pathology is characterized by lymphocytic infiltration and fibrosis, not eosinophilia or vasculitis.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: rural Peru origin, progressive dysphagia/regurgitation, 'bird's beak' esophagus, absent peristalsis, positive T. cruzi serology, dilated left ventricle with apical aneurysm. These findings are classic for chronic Chagas disease. The pathophysiology question is correctly answered by autoimmune destruction (B), which is the established mechanism for chronic Chagas cardiomyopathy and megaesophagus, not direct parasitic invasion. No logical issues; the stem provides all necessary details. Medical accuracy is high. Minimal fix: None required; the item is clear, accurate, and well-constructed.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\":  \t\n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: rural Peru origin, progressive dysphagia/regurgitation, 'bird's beak' esophagus, absent peristalsis, positive T. cruzi serology, dilated left ventricle with apical aneurysm. These findings are classic for chronic Chagas disease. The pathophysiology question is correctly answered by autoimmune destruction (B), which is the established mechanism for chronic Chagas cardiomyopathy and megaesophagus, not direct parasitic invasion. No logical issues; the stem provides all necessary details. Medical accuracy is high. Minimal fix: None required; the item is clear, accurate, and well-constructed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-016", "question": "A 62-year-old man with metastatic melanoma harboring BRAF V600E mutation has disease progression on combination dabrafenib/trametinib after 14 months. He is started on pembrolizumab. After 4 cycles, restaging shows mixed response with regression of most lesions but growth of a single hepatic metastasis. Biopsy of the progressing lesion reveals loss of β2-microglobulin expression. Which mechanism best explains resistance to pembrolizumab in this lesion?", "options": ["Upregulation of alternative immune checkpoints (LAG-3, TIM-3)", "Defective antigen presentation via MHC class I pathway", "Increased regulatory T-cell infiltration in the tumor microenvironment", "Activation of the WNT/β-catenin pathway excluding T-cells", "Loss of tumor neoantigens through immunoediting"], "answer": "B", "answer_index": 1, "explanation": "β2-microglobulin (B2M) is essential for MHC class I complex assembly and surface expression. Loss of B2M results in absent MHC class I expression, preventing CD8+ T-cell recognition of tumor antigens regardless of PD-1/PD-L1 blockade. This is a well-characterized mechanism of acquired resistance to checkpoint inhibitors. While alternative checkpoints, Tregs, WNT/β-catenin activation, and neoantigen loss can all contribute to immunotherapy resistance, the specific finding of B2M loss directly implicates defective MHC class I antigen presentation as the primary resistance mechanism in this lesion.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: metastatic BRAF V600E melanoma progressing on BRAF/MEK inhibitors, now on pembrolizumab (anti-PD-1) with mixed response; a single progressing liver lesion biopsied shows loss of β2-microglobulin expression. This specific molecular finding directly points to a defect in MHC class I antigen presentation, as β2-microglobulin is required for MHC I surface expression. The other options (A, C, D, E) describe plausible resistance mechanisms but are not directly supported by the biopsy result. No logical contradictions or missing critical details. Medical accuracy is high. Minimal fix: None required; the item is already clear and accurate.\",\n  \"medical_accuracy_score\":  \"5\",\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: metastatic BRAF V600E melanoma progressing on BRAF/MEK inhibitors, now on pembrolizumab (anti-PD-1) with mixed response; a single progressing liver lesion biopsied shows loss of β2-microglobulin expression. This specific molecular finding directly points to a defect in MHC class I antigen presentation, as β2-microglobulin is required for MHC I surface expression. The other options (A, C, D, E) describe plausible resistance mechanisms but are not directly supported by the biopsy result. No logical contradictions or missing critical details. Medical accuracy is high. Minimal fix: None required; the item is already clear and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-017", "question": "A 28-year-old woman with allergic rhinitis and mild persistent asthma on fluticasone/salmeterol presents for evaluation of recurrent anaphylaxis. She has experienced three episodes of anaphylaxis in the past year, each occurring 2-4 hours after eating, with no consistent food trigger identified. Episodes are characterized by flushing, hypotension, and abdominal cramping. Baseline serum tryptase is 6 ng/mL (normal <11.4). Skin prick testing to common food allergens is negative. During her most recent episode, serum tryptase was 28 ng/mL. Bone marrow biopsy shows scattered atypical mast cells expressing CD25. KIT D816V mutation is detected. Which diagnostic criterion confirms systemic mastocytosis in this patient?", "options": ["Elevated acute tryptase level during anaphylaxis", "Presence of CD25-positive mast cells on bone marrow biopsy", "Detection of KIT D816V mutation", "Baseline tryptase level above 20 ng/mL", "Multifocal dense mast cell aggregates (>15 mast cells) in bone marrow"], "answer": "E", "answer_index": 4, "explanation": "Diagnosis of systemic mastocytosis requires either the major criterion (multifocal dense aggregates of ≥15 mast cells in bone marrow or extracutaneous tissue) OR three minor criteria. Minor criteria include: >25% spindle-shaped/atypical mast cells, KIT D816V mutation, CD25/CD2 expression on mast cells, and baseline tryptase >20 ng/mL. This patient has two minor criteria (CD25 expression and KIT mutation) but needs either the major criterion or one more minor criterion. Her baseline tryptase of 6 ng/mL does not meet the minor criterion threshold. Finding dense mast cell aggregates (major criterion) would definitively confirm the diagnosis.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: The patient has recurrent anaphylaxis, elevated acute tryptase (28 ng/mL), and bone marrow findings of atypical CD25+ mast cells with KIT D816V mutation. According to WHO criteria for systemic mastocytosis, the major criterion is multifocal dense mast cell aggregates (>15 mast cells) in bone marrow or extracutaneous tissue, and minor criteria include atypical mast cell morphology, KIT D816V mutation, CD25 expression, and baseline tryptase >20 ng/mL. The stem states bone marrow biopsy shows 'scattered atypical mast cells expressing CD25' but does NOT confirm dense aggregates. Thus, the patient currently meets two minor criteria (CD25+ mast cells and KIT mutation) but not the major criterion or a third minor criterion. Option E (multifocal dense aggregates) would confirm the diagnosis, but it is not stated as present; it is a hypothetical finding. The keyed answer (E) is not supported by the vignette—no finding confirms diagnosis yet. The unique best answer from the given data is that no option confirms it, but if forced to choose based on criteria, option B or C are already met and do not alone confirm; E is the missing criterion. However, the question asks 'Which diagnostic criterion confirms...?' implying a criterion that, if present, would confirm. Since the vignette does not report E as present, the key is miskeyed. Main logical issue: The key selects an unconfirmed finding. Main medical accuracy: Minor issue—criteria are correctly stated, but the framing is confusing. Minimal fix: Change stem to 'Which finding from her evaluation confirms systemic mastocytosis?' and specify in vignette that bone marrow shows 'multifocal dense aggregates of >15 mast cells' to match key E.\",\n  \"logical_false_reason\": \"K\",\n  \"logical_validity\": false,\n  \"medical_accuracy_score\":  \t\n  \"4\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: The patient has recurrent anaphylaxis, elevated acute tryptase (28 ng/mL), and bone marrow findings of atypical CD25+ mast cells with KIT D816V mutation. According to WHO criteria for systemic mastocytosis, the major criterion is multifocal dense mast cell aggregates (>15 mast cells) in bone marrow or extracutaneous tissue, and minor criteria include atypical mast cell morphology, KIT D816V mutation, CD25 expression, and baseline tryptase >20 ng/mL. The stem states bone marrow biopsy shows 'scattered atypical mast cells expressing CD25' but does NOT confirm dense aggregates. Thus, the patient currently meets two minor criteria (CD25+ mast cells and KIT mutation) but not the major criterion or a third minor criterion. Option E (multifocal dense aggregates) would confirm the diagnosis, but it is not stated as present; it is a hypothetical finding. The keyed answer (E) is not supported by the vignette—no finding confirms diagnosis yet. The unique best answer from the given data is that no option confirms it, but if forced to choose based on criteria, option B or C are already met and do not alone confirm; E is the missing criterion. However, the question asks 'Which diagnostic criterion confirms...?' implying a criterion that, if present, would confirm. Since the vignette does not report E as present, the key is miskeyed. Main logical issue: The key selects an unconfirmed finding. Main medical accuracy: Minor issue—criteria are correctly stated, but the framing is confusing. Minimal fix: Change stem to 'Which finding from her evaluation confirms systemic mastocytosis?' and specify in vignette that bone marrow shows 'multifocal dense aggregates of >15 mast cells' to match key E.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-018", "question": "An 85-year-old man with heart failure with preserved ejection fraction, chronic kidney disease stage 3b, and type 2 diabetes is hospitalized for acute decompensated heart failure. He is treated with IV diuretics with good response. Prior to discharge, his medications are reviewed. His current regimen includes lisinopril 10 mg daily, metoprolol succinate 50 mg daily, empagliflozin 10 mg daily, and furosemide 40 mg twice daily. His eGFR is 38 mL/min/1.73m², potassium 4.8 mEq/L, and NT-proBNP 1,850 pg/mL (down from 5,200 on admission). Which medication adjustment is most strongly supported by evidence to reduce mortality in this patient?", "options": ["Add spironolactone 25 mg daily", "Increase lisinopril to 20 mg daily", "Add sacubitril/valsartan in place of lisinopril", "Add finerenone 10 mg daily", "Continue current regimen without changes"], "answer": "A", "answer_index": 0, "explanation": "The TOPCAT trial (Americas cohort) demonstrated mortality benefit with spironolactone in HFpEF. More importantly, the 2023 focused update to HF guidelines recommends MRAs (spironolactone/eplerenone) as a Class IIa recommendation for HFpEF to reduce hospitalizations. While finerenone has shown benefits in diabetic kidney disease, its role in HFpEF is less established than traditional MRAs. Sacubitril/valsartan (PARAGON-HF) showed benefit primarily in women and those with EF at the lower end of the HFpEF spectrum. With potassium 4.8 and eGFR 38, spironolactone can be safely initiated with monitoring. SGLT2 inhibitor is already optimized.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: HFpEF patient post-ADHF, CKD 3b, diabetes, on GDMT (ACEi, beta-blocker, SGLT2i, diuretic), eGFR 38, K+ 4.8. The question asks for the adjustment most strongly supported by evidence to reduce mortality. The keyed answer (A, spironolactone) is not the single best answer. For HFpEF, the strongest mortality evidence supports an SGLT2 inhibitor (empagliflozin, already present) based on EMPEROR-Preserved and DELIVER trials. Spironolactone (TOPCAT) primarily showed benefit for reducing heart failure hospitalizations, not a clear mortality benefit, and its evidence is less robust than SGLT2i. Finerenone (D) has mortality benefit in diabetic CKD but not specifically established for HFpEF mortality. Continuing current regimen (E) is a strong contender given the patient is already on foundational, evidence-based therapy. This creates a defensible argument for E, making A miskeyed. Main logical issue: Key mismatch. Main medical accuracy issue: Overstates mortality evidence for spironolactone in HFpEF. Minimal fix: Change the key to E (Continue current regimen) or, to make A best, rephrase the stem to ask for the best medication to add to reduce heart failure hospitalizations.\",\n  \"medical_accuracy_score\":  \"3\",\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: HFpEF patient post-ADHF, CKD 3b, diabetes, on GDMT (ACEi, beta-blocker, SGLT2i, diuretic), eGFR 38, K+ 4.8. The question asks for the adjustment most strongly supported by evidence to reduce mortality. The keyed answer (A, spironolactone) is not the single best answer. For HFpEF, the strongest mortality evidence supports an SGLT2 inhibitor (empagliflozin, already present) based on EMPEROR-Preserved and DELIVER trials. Spironolactone (TOPCAT) primarily showed benefit for reducing heart failure hospitalizations, not a clear mortality benefit, and its evidence is less robust than SGLT2i. Finerenone (D) has mortality benefit in diabetic CKD but not specifically established for HFpEF mortality. Continuing current regimen (E) is a strong contender given the patient is already on foundational, evidence-based therapy. This creates a defensible argument for E, making A miskeyed. Main logical issue: Key mismatch. Main medical accuracy issue: Overstates mortality evidence for spironolactone in HFpEF. Minimal fix: Change the key to E (Continue current regimen) or, to make A best, rephrase the stem to ask for the best medication to add to reduce heart failure hospitalizations.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}]